Phaseline

Targets › MTOR

MTOR (Serine/threonine-protein kinase mTOR): drug programs, companies and trials

11 programs from 11 companies in 29 trials: 14 Phase 2, 11 Phase 1, 4 Phase 3; Oncology, Cardiovascular, Infectious disease; next expected readout Dec 2026.

Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. (UniProt, P42345)

Open in Phaseline: the race on MTOR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CelcuityGedatolisib
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 3Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast CancerDec 2026
iVascular S.L.U.Angiolite
Sirolimus-eluting stent with thin-strut cobalt-chromium, open-cell design, durable biostab
MTORPhase 3Coronary Artery DiseaseJan 2027
Palvella TherapeuticsQTORIN 3.9% Rapamycin Anhydrous Gel
mTOR inhibitor
MTORPhase 3Microcystic Lymphatic Malformation–
Supernus PharmaceuticalsSPN-821
selective, direct enhancer of mTORC1 cellular signaling
MTORPhase 2Major Depressive Disorder (MDD)Dec 2026
Theodore S. JohnsonIndoximod
mTORC1 activator
MTOR, RPTOR, MLST8Phase 2Glioblastoma; EpendymomaDec 2027
David Reardon, MDCC-115
mTOR and ATM kinase inhibitor
MTOR, ATMPhase 2GlioblastomaFeb 2028
Faeth TherapeuticsSapanisertib
Serine/threonine-protein kinase mTOR inhibitor
MTORPhase 2Endometrial Cancer; HR+ HER2- Breast Cancer; Locally Advanced Bladder Urothelial Carcinoma; Advanced Lymphoma …Sep 2028
RestorbioDactolisib (BEZ235)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 2Respiratory Tract Infections; Covid19–
AstraZenecaVistusertib
Serine/threonine-protein kinase mTOR inhibitor
MTORPhase 2Non-Small Cell Lung Cancer; Meningioma; Metastatic Breast Cancer; BRCA1 Mutation Carrier–
Eli LillySamotolisib (LY3023414)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 1Breast Neoplasms; Endometrial CancerDec 2026
SAPU NANO (US)Sapu003
mTOR inhibitor
MTORPhase 1Breast Cancer MetastaticDec 2026

Conditions

Endometrial Cancer (3) Advanced Lymphoma (2) Glioblastoma (2) Breast Cancer (2) Coronary Artery Disease (1) Respiratory Tract Infections (1) Covid19 (1) HR+ HER2- Breast Cancer (1) Locally Advanced Bladder Urothelial Carcinoma (1) Adult Glioblastoma (1) Leptomeningeal Neoplasm (1) Metastatic Lung Non-Small Cell Carcinoma (1)

Modalities

small molecule (9), mixed (2)

Companies

iVascular S.L.U. (1) Restorbio (1) Faeth Therapeutics (1) Theodore S. Johnson (1) Celcuity (1) Palvella Therapeutics (1) Supernus Pharmaceuticals (1) SAPU NANO (US) (1) David Reardon, MD (1) Eli Lilly (1) AstraZeneca (1)

Related targets

PIK3R1 (3) PIK3CB (3) PIK3CG (3) PIK3CA (3) RPTOR (1) MLST8 (1) ATM (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.